Optimal Assignment of Treatments to??Health States Using a Markov Decision Model

作者: Mohan V Bala , Josephine A Mauskopf

DOI: 10.2165/00019053-200624040-00005

关键词: Markov chainMedicineHealth carePartially observable Markov decision processMarkov decision processOperations researchHealth interventionCost effectivenessMarkov modelDecision modelPublic Health, Environmental and Occupational HealthHealth policyPharmacology

摘要: Assessing the cost effectiveness of a new health intervention often requires modelling to estimate impact on cost, survival and quality life over lifetime cohort patients. Markov is methodology that commonly employed these long-term costs benefits. As used, models assume patients continue get treatments assigned regardless change in states. In this paper, we describe an extension approach, called decision modelling. Such model starts with set states optimally assigns each A can be used identify optimal treatment strategy not just for initial disease state, but also as state changes time. We present dynamic programming approach identifying assignment treatments, illustrate using example. The provides efficient way states, but, like standard model, may limited use when probabilities future events depend past history complex fashion. Even its limitations, offer opportunity economists inform healthcare decision-makers how modify current pathways incorporate they become available.

参考文章(18)
Teresa Kauf, Mari Kitahata, Josephine Mauskopf, Anke Richter, Jerry Tolson, HIV antiretroviral treatment: early versus later. Journal of Acquired Immune Deficiency Syndromes. ,vol. 39, pp. 562- 569 ,(2005)
Bruce R. Schackman, Sue J. Goldie, Milton C. Weinstein, Elena Losina, Hong Zhang, Kenneth A. Freedberg, Cost-Effectiveness of Earlier Initiation of Antiretroviral Therapy for Uninsured HIV-Infected Adults American Journal of Public Health. ,vol. 91, pp. 1456- 1463 ,(2001) , 10.2105/AJPH.91.9.1456
David Henry, Economic Analysis as an Aid to Subsidisation Decisions PharmacoEconomics. ,vol. 1, pp. 54- 67 ,(1992) , 10.2165/00019053-199201010-00010
Rajiv Sharma, Miron Stano, Mitchell Haas, Adjusting to changes in health: implications for cost-effectiveness analysis. Journal of Health Economics. ,vol. 23, pp. 335- 351 ,(2004) , 10.1016/J.JHEALECO.2003.12.004
Joshua A Salomon, Milton C Weinstein, Sue J Goldie, None, Taking account of future technology in cost effectiveness analysis. BMJ. ,vol. 329, pp. 733- 736 ,(2004) , 10.1136/BMJ.329.7468.733
K. Claxton, K.M. Thompson, A dynamic programming approach to the efficient design of clinical trials. Journal of Health Economics. ,vol. 20, pp. 797- 822 ,(2001) , 10.1016/S0167-6296(01)00093-5
Mohan V Bala, Gary A Zarkin, On pharmacogenomics and cost-effectiveness analysis at the individual level. PharmacoEconomics. ,vol. 23, pp. 527- 527 ,(2005) , 10.2165/00019053-200523050-00011